Equillium (Nasdaq: EQ) announced that preclinical data for EQ504 will be presented as posters at IMMUNOLOGY2026™, April 15-19 in Boston. Two posters focus on EQ504 as a potent AhR modulator promoting immune tolerance (IL-10/IL-22) and epithelial barrier repair.
Presentations occur April 16 (Poster 242; speaker 2:30-3:30 PM EDT) and April 18 (Poster 517; speaker 11:30 AM-12:30 PM EDT); posters will be posted on the company Presentations page after each session.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – EQ
-6.25%
4 alerts
-6.25%Session close to close
$121.39MMarket Cap
0.3xRel. Volume
In the Apr 8 session, EQ declined 6.25%, reflecting a notable negative market reaction.
Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
The stock moved -6.3% in the session following this news. A negative reaction despite mechanistic EQ...
Analysis
The stock moved -6.3% in the session following this news. A negative reaction despite mechanistic EQ504 data would fit a pattern where funding structures and overhangs weigh on sentiment. Recent filings describe a preclinical-stage strategy centered on EQ504 and note a Form S-3 covering 18,878,101 shares for resale tied to the March 2026 financing. Investors typically watch how such registered blocks and upcoming early-stage trial readouts interact with volatility.
Key Figures
Conference dates:April 15–19, 2026Poster 1 session time:9:00 AM – 4:30 PM EDTPoster 1 board number:242+4 more
7 metrics
Conference datesApril 15–19, 2026IMMUNOLOGY2026™ annual meeting dates in Boston
Poster 1 session time9:00 AM – 4:30 PM EDTEQ504 immune response poster session on April 16, 2026
Poster 1 board number242Poster board number for first EQ504 presentation
Poster 1 speaker window2:30 PM – 3:30 PM EDTSpeaker time for first EQ504 poster
Poster 2 session time9:00 AM – 4:30 PM EDTEQ504 epithelial repair poster session on April 18, 2026
Poster 2 board number517Poster board number for second EQ504 presentation
Poster 2 speaker window11:30 AM – 12:30 PM EDTSpeaker time for second EQ504 poster
Announced participation in Leerink Partners healthcare conference and investor meetings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
EQ has generally traded in line with neutral and financing headlines, with one divergence on a more negative earnings update.
Recent Company History
Over the last few months, Equillium issued several corporate updates, including conference participations, an inducement option grant, and a $35M private placement tied to EQ504 development. Earnings showed a shift to a development-stage profile with no 2025 revenue and a $22.4M net loss. The new IMMUNOLOGY2026™ EQ504 preclinical posters build on this focus, highlighting mechanistic data ahead of the planned Phase 1 proof-of-mechanism study in mid-2026.
Key Terms
ahr modulator, immune tolerance, il-10, il-22, +4 more
8 terms
ahr modulatormedical
"EQ504 as a potent AhR modulator, with the potential to influence both immune..."
An AHR modulator is a compound that adjusts the activity of the aryl hydrocarbon receptor, a protein inside cells that helps control how genes respond to environmental signals and stress. For investors, these drugs are important because they can be developed to treat inflammation, immune disorders, or certain cancers, but they also carry safety and regulatory risks since the receptor affects many body systems; think of it as a dimmer switch that needs precise tuning to avoid unwanted effects.
immune tolerancemedical
"A Novel AhR Modulator That Promotes Immune Tolerance Through Il-10 and Il-22..."
Immune tolerance is the immune system’s ability to ignore harmless or self tissues so it does not attack the body or beneficial therapies; think of it as the immune system learning to leave trusted neighbors alone. For investors, therapies that restore or induce immune tolerance can prevent chronic autoimmune damage, reduce rejection after transplants, and lower long-term drug side effects, making them high-impact targets with potential for durable clinical benefit and cost savings.
il-10medical
"Promotes Immune Tolerance Through Il-10 and Il-22 Cytokine Release"
IL-10 is a small signaling protein the immune system uses to dial down inflammation, acting like a thermostat that tells immune cells to calm down to prevent excessive damage. For investors, IL-10 matters because therapies that boost, mimic, or block its activity can change how well treatments work, affect safety profiles, guide clinical trial design, and influence regulatory and commercial prospects for drugs targeting inflammatory and immune-related diseases.
il-22medical
"Promotes Immune Tolerance Through Il-10 and Il-22 Cytokine Release"
IL-22 is a small signaling protein made by immune cells that tells tissues — especially skin, lung and gut cells — to change how they grow, repair themselves and respond to inflammation. Investors pay attention because IL-22 can be a target for new drugs or a biomarker in clinical trials: therapies that boost or block IL-22 may change disease outcomes, so trial results and regulatory decisions around IL-22 programs can materially affect a biotech firm’s value.
cytokinemedical
"Immune Tolerance Through Il-10 and Il-22 Cytokine Release"
Small proteins produced by cells that act as chemical messengers to coordinate immune and inflammatory responses, like text messages or traffic signals telling cells when to activate, calm down, or move. Investors care because cytokines are common drug targets and biomarkers; changes in cytokine activity can determine a therapy’s effectiveness, safety, regulatory approval, and market potential, so trial results or safety signals tied to cytokines often drive stock moves.
ulcerative colitismedical
"important in diseases such as ulcerative colitis, where both reducing inflammation..."
A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.
epithelial repairmedical
"EQ504, a Potent AhR Modulator, Promotes Epithelial Repair and Barrier Restoration..."
Epithelial repair is the process by which the thin layer of cells that lines organs, skin or internal surfaces regrows and seals after injury or disease. Investors care because therapies or products that speed or improve this healing can reduce complications, shorten recovery time and serve as measurable clinical benefits or regulatory endpoints—think of it like patching a roof quickly and tightly to prevent leaks and further damage.
barrier restorationmedical
"Promotes Epithelial Repair and Barrier Restoration Compared to Clinically..."
Barrier restoration is the process of repairing and strengthening the body’s protective layers—most commonly the skin or the gut—so they keep in moisture, keep out irritants and microbes, and return to normal function. For investors, products or therapies that deliver reliable barrier restoration matter because they can reduce chronic symptoms, lower ongoing treatment needs, improve regulatory and reimbursement prospects, and create steady demand much like fixing a leaky roof prevents recurring damage and future costs.
LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new EQ504 preclinical data have been accepted for poster presentations at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists taking place in Boston, Massachusetts, April 15-19, 2026.
“We are excited to share these preclinical findings that support the differentiated profile of EQ504 as a potent AhR modulator, with the potential to influence both immune cell responses and barrier restoration,” said Dr. Stephen Connelly, Chief Scientific Officer of Equillium. “Together, these attributes are particularly important in diseases such as ulcerative colitis, where both reducing inflammation and improving mucosal healing are critical to achieving meaningful outcomes for patients.”
Details of the presentations:
Abstract title:EQ504: A Novel AhR Modulator That Promotes Immune Tolerance Through Il-10 and Il-22 Cytokine Release Session: Immune Response Regulation: Cellular Mechanisms I Presentation Type: Poster Abstract Presentation Presentation Location & Time: Exhibit Hall, Thursday April 16, 2026 Session Time: 9:00 AM - 4:30 PM EDT Poster Board Number: 242 Speaker at Poster: 2:30 PM - 3:30 PM EDT
Abstract title:EQ504, a Potent AhR Modulator, Promotes Epithelial Repair and Barrier Restoration Compared to Clinically Validated AhR Agonists Session: Immunology of Barrier Surfaces Presentation Type: Poster Abstract Presentation Presentation Location & Time: Exhibit Hall, Saturday April 18, 2026 Session Time: 9:00 AM - 4:30 PM EDT Poster Board Number: 517 Speaker at Poster: 11:30 AM - 12:30 PM EDT
Following each presentation, the posters will be available on the Presentations page, located under the Technology section on equilliumbio.com.
About EQ504 EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504’s preclinical properties provide the potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.
About Equillium Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor (AhR) modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. EQ504 is an investigational therapeutic program with potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.
What EQ504 preclinical findings will Equillium (EQ) present at IMMUNOLOGY2026?
EQ504 preclinical data show immune tolerance via increased IL-10 and IL-22 release and enhanced epithelial repair. According to Equillium, the posters highlight EQ504 as a potent AhR modulator that may reduce inflammation and promote mucosal healing in diseases like ulcerative colitis.
When and where will Equillium (EQ) present the EQ504 posters at IMMUNOLOGY2026?
Equillium will present at IMMUNOLOGY2026 in Boston on April 16 and April 18, 2026. According to Equillium, both posters are in the Exhibit Hall with Poster 242 on April 16 (speaker 2:30-3:30 PM EDT) and Poster 517 on April 18 (speaker 11:30 AM-12:30 PM EDT).
How can investors access Equillium (EQ) EQ504 posters after IMMUNOLOGY2026 presentations?
Posters will be posted online on the company's Presentations page after each session. According to Equillium, the posters will appear under the Technology section on equilliumbio.com following the April 16 and April 18 presentations.
What topics do Equillium's (EQ) two EQ504 posters cover at IMMUNOLOGY2026?
One poster covers immune response regulation showing IL-10 and IL-22 cytokine release; the other compares epithelial repair and barrier restoration versus validated AhR agonists. According to Equillium, both focus on EQ504's differentiated AhR modulatory profile and barrier-restorative potential.
Will there be scheduled speaker times for Equillium's (EQ) EQ504 posters at IMMUNOLOGY2026?
Yes, each poster has a scheduled speaker period during the exhibit session. According to Equillium, Poster 242 has a speaker at 2:30-3:30 PM EDT on April 16 and Poster 517 at 11:30 AM-12:30 PM EDT on April 18.
